Quick Answer
Cue Biopharma, Inc. reported Net Income of -$26.60 million for fiscal year 2025.
Cue Biopharma, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$26.60M | +34.6% |
| 2024 | -$40.67M | +19.8% |
| 2023 | -$50.73M | +4.3% |
| 2022 | -$53.01M | -20.0% |
| 2021 | -$44.16M | +1.4% |
| 2020 | -$44.78M | -22.0% |
| 2019 | -$36.70M | +5.9% |
| 2018 | -$38.98M | -67.8% |
| 2017 | -$23.23M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.45M | +14.0% | +12.2% |
| June 30, 2025 | -$8.48M | +16.6% | +30.8% |
| March 31, 2025 | -$12.26M | +0.7% | -41.5% |
| September 30, 2024 | -$8.66M | +21.3% | +14.9% |
| June 30, 2024 | -$10.17M | +22.9% | +17.6% |
| March 31, 2024 | -$12.35M | +5.8% | -12.2% |
| September 30, 2023 | -$11.01M | -0.5% | +16.5% |
| June 30, 2023 | -$13.19M | +0.2% | -0.6% |
- Cue Biopharma, Inc. showed an increase of +34.6% in Net Income compared to the prior fiscal year.
- Over the 2017–2025 period, Cue Biopharma, Inc.’s net income has declined by 14.5% (from -$23.23 million to -$26.60 million).
- The most recent figure is from Cue Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: